• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.

    4/7/26 7:21:40 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OKUR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    OnKure Therapeutics, Inc.

    (Name of Issuer)


    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    68277Q105

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    68277Q105


    1Names of Reporting Persons

    StepStone Group LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,660,612.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,660,612.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,660,612.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    68277Q105


    1Names of Reporting Persons

    StepStone Master G, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,660,612.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,660,612.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,660,612.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    68277Q105


    1Names of Reporting Persons

    StepStone VC MI-G GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,660,612.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,660,612.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,660,612.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.6 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    OnKure Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    6707 Winchester Circle #400 Boulder, CO 80301
    Item 2. 
    (a)Name of person filing:

    The name of the persons filing this report (the "Reporting Persons") are: (i) StepStone Group LP ("StepStone"); (ii) StepStone Master G, L.P. ("Master G"); and (iii) StepStone VC MI-G GP, LLC ("MI-G GP"). MI-G GP is the general partner of Master G. StepStone is the sole managing member of MI-G GP. StepStone is the investment manager of each of Master G and MI-G GP. StepStone Group Holdings LLC ("StepStone Group Holdings") is the general partner of StepStone, and StepStone Group Inc. is the sole managing member of StepStone Group Holdings.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 4225 Executive Square, Suite 1600 La Jolla, CA 92037
    (c)Citizenship:

    Each of StepStone and Master G is a limited partnership organized under the laws of the State of Delaware. MI-G GP is a limited liability company organized under the laws of the State of Delaware.
    (d)Title of class of securities:

    Class A Common Stock, par value $0.0001 per share
    (e)CUSIP Number(s):

    68277Q105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 40,395,478 shares of Common Stock outstanding as of April 1, 2026, as provided by the Issuer.
    (b)Percent of class:

    See Item 4(a) above
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 4(a) above

     (ii) Shared power to vote or to direct the vote:

    See Item 4(a) above

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 4(a) above

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 4(a) above

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    StepStone Group LP
     
    Signature:By: StepStone Group Holdings LLC, its general partner
    Name/Title:Jennifer Y. Ishiguro Partner, Chief Legal Officer
    Date:04/07/2026
     
    Signature:/s/ Jennifer Y. Ishiguro
    Name/Title:Jennifer Y. Ishiguro Partner, Chief Legal Officer
    Date:04/07/2026
     
    StepStone Master G, L.P.
     
    Signature:By: StepStone Group LP, its investment manager
    Name/Title:Jennifer Y. Ishiguro Partner, Chief Legal Officer
    Date:04/07/2026
     
    Signature:By: Stepstone Group Holdings LLC, its general partner
    Name/Title:Jennifer Y. Ishiguro Partner, Chief Legal Officer
    Date:04/07/2026
     
    Signature:/s/ Jennifer Y. Ishiguro
    Name/Title:Jennifer Y. Ishiguro Partner, Chief Legal Officer
    Date:04/07/2026
     
    StepStone VC MI-G GP, LLC
     
    Signature:By: StepStone Group LP, its investment manager
    Name/Title:Jennifer Y. Ishiguro Partner, Chief Legal Officer
    Date:04/07/2026
     
    Signature:By: Stepstone Group Holdings LLC, its general partner
    Name/Title:Jennifer Y. Ishiguro Partner, Chief Legal Officer
    Date:04/07/2026
     
    Signature:/s/ Jennifer Y. Ishiguro
    Name/Title:Jennifer Y. Ishiguro Partner, Chief Legal Officer
    Date:04/07/2026
    Get the next $OKUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OKUR

    DatePrice TargetRatingAnalyst
    4/30/2025Outperform
    Evercore ISI
    12/5/2024$33.00Outperform
    Leerink Partners
    10/10/2024$35.00Outperform
    Oppenheimer
    More analyst ratings

    $OKUR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.

    SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

    4/7/26 7:21:40 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.

    SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

    4/7/26 4:30:29 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by OnKure Therapeutics Inc.

    SCHEDULE 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

    4/7/26 4:13:47 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

    -- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer and vascular anomalies – expect to file INDs for each program in 1H 2027 -- Liam Ratcliffe Joins OnKure's Board of Directors BOULDER, Colo., March 27, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of a

    3/27/26 8:00:00 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

    -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with trastuzumab and tucatinib in patients with metastatic breast cancer -- Clinical data from OKI-219 PIKture-01 single agent and fulvestrant combination arms are maturing and is now expected to be reported together with initial data from the triplet expansion arms in the first quarter of 2026 -- Significant progress in next-generation PI3Kα pan-mutant inhibitor program; multiple candidates identified - announcement planned for the first quarter of 2026 -- Expansion into Vascular Malformations - additional information to be provid

    11/6/25 4:03:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure Therapeutics to Participate in Upcoming Investor Conferences

    BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that Nichoals Saccomano, Ph.D., President and Chief Executive Officer, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Guggenheim Healthcare Innovation Conference, in Boston on Monday, November 10, 2025, at 4:00 p.m. ET. A live audio webcast will be available through this link. A corporate presentation at the Stifel Healthcare Conference, in New York on November 12, 2025, at 4:00 p.m. ET. A live audio webcast

    11/4/25 4:05:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Ai Biotechnology Llc

    3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    4/7/26 9:15:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Saccomano Nicholas A

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    4/3/26 3:29:11 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Leverone Jason A.

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    4/3/26 3:27:44 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on OnKure Therapeutics

    Evercore ISI initiated coverage of OnKure Therapeutics with a rating of Outperform

    4/30/25 8:12:14 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on OnKure Therapeutics with a new price target

    Leerink Partners initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $33.00

    12/5/24 8:06:23 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on OnKure Therapeutics with a new price target

    Oppenheimer initiated coverage of OnKure Therapeutics with a rating of Outperform and set a new price target of $35.00

    10/10/24 7:48:05 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Acorn Bioventures, L.P. bought $2,590,000 worth of shares (1,400,000 units at $1.85) (SEC Form 4)

    4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

    5/19/25 4:43:34 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Leadership Updates

    Live Leadership Updates

    View All

    OnKure Announces New Date for Upcoming Investor Call

    BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10th. OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. E

    11/25/24 5:31:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Financials

    Live finance-specific insights

    View All

    OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

    -- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or discontinuations were reported -- Initial patient data show exposures of OKI-219 exceeding levels associated with robust antitumor activity in preclinical models -- Data support the initiation of Part 1b of PIKture-01 evaluating OKI-219 in combination with fulvestrant; first patients dosed, and initial data are expected in 2H-2025 -- Management to host conference call today, December 10, 2024 at 7:00 a.m. CT BOULDER, Colo., Dec. 10, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medi

    12/10/24 7:00:00 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

    OnKure to host a conference call to review key data presented at SABCS and provide a general corporate update on Friday, December 13, 2024 at 8:00 a.m. ET BOULDER, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that two abstracts discussing preliminary clinical data and preclinical data for OKI-219, a potential best-in-class, mutant-selective PI3KαH1047R inhibitor, have been selected for presentation during poster sessions at the 2024 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in person from D

    11/1/24 5:30:00 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OKUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

    SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/14/24 4:00:05 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OnKure Therapeutics Inc.

    SC 13G - OnKure Therapeutics, Inc. (0001637715) (Subject)

    11/14/24 10:11:45 AM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OnKure Therapeutics Inc.

    SC 13G/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

    10/28/24 4:03:06 PM ET
    $OKUR
    Biotechnology: Pharmaceutical Preparations
    Health Care